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S U M M A R Y
Background: In adults with Staphylococcus aureus bacteraemia, short duration of effec-
tive antibiotic treatment is associated with increased risk of complications and recur-
rence. The optimum duration of treatment for neonates is unknown and practice varies
widely.
Aim: To relate the duration of treatment of neonatal S. aureus bacteraemia to prevention
of complications and recurrence.
Methods: Retrospective cohort study of confirmed S. aureus bacteraemia occurring over a 10
year period in two large tertiary neonatal units. Neonatal patients developing confirmed
S. aureus bacteraemia between birth and discharge from the neonatal unit were identified
from microbiology department records. Clinical details obtained from case notes included
demographics, duration of antibiotics and clinical outcomes. Recurrence was determined
from laboratory and clinical records. Adverse outcomes were related to duration of antibiotic
therapy.
Findings: A total of 90 infants had S. aureus bacteraemia, of which six were meticillin-
resistant S. aureus (7%). Median gestation was 27 weeks (range: 23e41), birth weight
846 g (434e3840) and postnatal age 16 days (0e116). Adverse outcomes were found in 44%,
with death in 8%. Median duration of appropriate antibiotics was 19 days (range: 0e54).
There were no cases of recurrent bacteraemia after finishing antibiotics. There was no
relationship between antibiotic duration and complications.
Conclusion: Neonatal S. aureus bacteraemia mainly affected preterm neonates and had a
significant morbidity and mortality. Recurrent bacteraemia was rare, irrespective of
treatment duration. For neonatal unit patients with S. aureus bacteraemia, antibiotic
therapy for 14 days in uncomplicated cases may be sufficient to prevent recurrence, with
longer treatment justified if there is inadequate source control.
ª 2015 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
* Corresponding author. Address: Centre for Paediatrics, Blizard Institute, Barts and the London School of Medicine and Dentistry, 4 Newark
Street, London E1 2AT, UK. Tel.: þ44 (0)20 7882 2615; fax: þ44 (0)20 7882 2195.
E-mail address: s.t.kempley@qmul.ac.uk (S. Kempley).
Available online at www.sciencedirect.com
Journal of Hospital Infection
journal homepage: www.elsevierhealth.com/journals / jhin
http://dx.doi.org/10.1016/j.jhin.2015.07.002
0195-6701/ª 2015 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
Journal of Hospital Infection xxx (2015) 1e7
Please cite this article in press as: Kempley S, et al., Antibiotic treatment duration and prevention of complications in neonatal Staphylococcus
aureus bacteraemia, Journal of Hospital Infection (2015), http://dx.doi.org/10.1016/j.jhin.2015.07.002
Introduction
Neonatal Staphylococcus aureus bacteraemia and sepsis
remain important clinical problems. Recent surveillance re-
ported S. aureus as second only to coagulase-negative staph-
ylococcus as the cause of neonatal bacteraemia in the UK, and
device-associated neonatal bacteraemia in the USA.1,2 Of these
isolates, 8% in the UK and 33% in the USA were meticillin-
resistant (MRSA). A review of community-acquired neonatal
sepsis in developing countries found S. aureus to be the most
prevalent pathogen isolated.3
In adults, S. aureus bacteraemia is frequently associated
with metastatic disease, affecting heart valves, joints, kid-
neys, and central nervous system, contributing to morbidity
and acting as a reservoir for recurrent disease.4 Recurrence is
high if central lines are not removed.5 Some studies have
demonstrated links between shorter treatment duration and
recurrent disease, but others have not.5,6 A recent review
highlighted the lack of clear evidence for most aspects of
S. aureus bacteraemia management in adults, with only one
randomized trial directly addressing antibiotic therapy dura-
tion.7,8 Their only clear conclusions were that infective foci
must be identified and removed if possible, and that long-term
antimicrobial therapy is required for persistent bacteraemia or
an irremovable focus.
Recommended duration of therapy in adults depends on
whether disease is complicated or uncomplicated. Complicated
disease is defined by a positive follow-up blood culture at
48e96 h, community-acquired infection, persistent fever at
72 h or skin lesions suggesting systemic infection. Uncompli-
cated disease is indicated by catheter-associated infectionwith
removal of the catheter, negative follow-up blood culture,
defervescence within 72 h, normal transoesophageal echocar-
diogram, no prostheticmaterial in joints or intravascular space,
and no symptoms suggesting metastatic infection.9
Recent guidelines have been produced for treating MRSA
bacteraemia in adults and children. Guidance from the UK
recommended 14 days of treatment for uncomplicated MRSA
bacteraemia and longer for complicated disease, with no spe-
cific guidance for children.10 The Infectious Diseases Society of
America recommended two weeks of treatment for uncompli-
cated MRSA bacteraemia and four to six weeks for complicated
adult cases. In children they recommended intravenous van-
comycin for two to six weeks with MRSA bacteraemia or proven
endocarditis, with no specific recommendations for therapy
duration in neonates.11
Prevention of recurrence is an important element within
strategies to reduce the burden of hospital-acquired S. aureus
infection in adults. There is little known about the burden of
recurrent disease in neonatal unit populations or how it is
influenced by antibiotic treatment duration. Several aspects of
immune function in neonates explain their susceptibility to
S. aureus infection. They rely on maternal IgG transferred
across the placenta, which may be deficient if they are deliv-
ered prematurely.12 Neonates have reduced complement
function, neutrophil chemotaxis and bacterial killing, sug-
gesting that they may need longer therapy to prevent recur-
rence.13,14 This study aims to examine outcomes following
S. aureus bacteraemia in neonates, relating the duration of
antibiotic treatment to complications and recurrence.
Methods
Procedures
Laboratory microbiology databases were used to identify all
cases of S. aureus bacteraemia in admissions to two large
neonatal units over a 10-year period (2001e2010). When posi-
tive S. aureus cultures were taken, all infants were inpatients
in the neonatal unit of either the Homerton Hospital (48 cases)
or the Royal London Hospital (42 cases) in East London, UK.
These provide neonatal care for their local populations and also
take external medical and surgical referrals as tertiary
neonatal intensive care units. Neither unit had standard guid-
ance on duration of therapy for S. aureus bacteraemia and
clinicians made decisions on an individual basis in conjunction
with medical microbiologists.
Bacteraemia was defined by the isolation of S. aureus from a
blood culture, taken from a peripheral vein. The units prac-
tised standard aseptic procedures for blood culture collection
with skin preparation using a 70% isopropyl alcohol swab. Blood
cultures were processed in accredited laboratories using
standard operating procedures and automated systems. During
this study, S. aureus isolates were not routinely tested for
toxins. Clinical sepsis was defined as bacteraemia treated with
antibiotics with clinical signs or a raised C-reactive protein
(CRP). The study received approval from the clinical gover-
nance committees of both institutions (Reference nos.: 614/
670 Homerton, 081-11 Royal London).
Clinical details were extracted from medical records, to
identify risk factors at the time of infection and outcomes.
Prior specified adverse outcomes were death, bacterial
endocarditis, osteomyelitis, renal abscess, meningitis, brain
abscess, pneumatocoele, duration of oxygen requirement,
and recurrent S. aureus infection either during admission or
during paediatric admission in the first year of life. Other non-
specified complications and adverse outcomes were
recorded.
Appropriate antibiotics were defined as those to which the
organism was identified as susceptible by standard methods
(British Society for Antimicrobial Chemotherapy, Birmingham,
UK). For orally absorbable drugs such as flucloxacillin, dura-
tion of appropriate antibiotics was the total of intravenous
and oral.
Recurrence was defined as any clinical illness with isolation
of S. aureus after stopping appropriate antibiotic therapy,
recorded in the hospital or laboratory record during the first
year of life, including both bacteraemia and localized disease.
Breakthrough disease was defined as a positive S. aureus
culture during the primary antibiotic course. Classical
S. aureus disease was defined as abscess, osteomyelitis,
impetigo, or scalded skin syndrome. Complicated disease was
defined as S. aureus bacteraemia with a central line or
implanted device which was not removed, or a focus which
was hard for antibiotics to penetrate, such as a deep-seated
abscess, or metastatic sites of infection. For three patients
only, there was a protected focus (abscess or endocarditis),
which could have arisen after the infection, or may have been
present in a cryptic state before diagnosis. These cases were
recorded as having an adverse outcome and complicated
disease.
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Statistical analysis
Statistical analysis was performed to determine effects of
appropriate antibiotic therapy duration on outcomes and
recurrent infection. Patients who died while still receiving
antibiotics were excluded from this analysis, as their treatment
course was curtailed by death. Patients were divided into three
groups according to antibiotic duration: <14 days, 14e27 days
and >27 days. As several variables showed a skewed distribu-
tion, comparisons between groups were made using Krus-
kalleWallis test for continuous variables and chi-square or
Fisher’s exact tests for categorical variables. Logistic regres-
sion was performed with adverse outcome as the dependent
variable, and independent variables of birth weight, gender,
meticillin-susceptibility, maximum CRP, antibiotic duration,
and presence of complicated disease. All tests were performed
using IBM SPSS Statistics v21.
Results
A total of 90 infants with S. aureus bacteraemia were
identified, of which six (7%) were MRSA. There was a prepon-
derance of low gestation and birth weight (Table I), with me-
dian gestation of 27 weeks and median birth weight of 846 g.
Although median postnatal age was 16 days, peak incidence
was in the second week of life (Figure 1).
An underlying diagnosis classically associated with S. aureus
infection was reported in 10 cases (11%); these were cellulitis
or abscess (8), bone or joint infection (1) and line infection (1).
In nine cases (10%) there was pneumonia, which may be asso-
ciated with S. aureus. Other diagnoses not normally associated
with S. aureus included necrotizing enterocolitis and abdom-
inal surgery (9), and congenital abnormality (5). Complicated
S. aureus infection was found in 17 (19%).
Adverse outcomes were found in 40 cases (44%), which
included recurrent or breakthrough S. aureus infection (4),
death (7), osteomyelitis (2), limb shortening (1), meningitis (4),
bacterial endocarditis (1), pneumatocoeles (1), surgical
drainage of abscesses (2), necrotizing enterocolitis after the
initial illness (6), and increased duration of oxygen require-
ment (16). Some had more than one adverse outcome.
Recurrent infection
There were no cases of recurrent S. aureus bacteraemia
after completing the primary antibiotic course. Two infants
had non-bacteraemic recurrent S. aureus infection; one with a
respiratory infection requiring reintubation in the neonatal
unit, the other with S. aureus otitis media during readmission
to paediatric wards.
Two patients had breakthrough S. aureus infection during
their primary antibiotic course. One had breakthrough
S. aureus bacteraemia six days after starting antibiotics; this
infant was colonized with S. aureus at birth and had S. aureus
cultured from maternal expressed milk, so may have been
reinfected. Another preterm infant with osteomyelitis had
S. aureus cultured locally from abscesses eight days after
starting treatment. There were no differences in clinical
characteristics or antibiotic duration between those with
recurrent or breakthrough disease and the remaining cohort.
Antibiotic duration and adverse outcomes
Appropriate antibiotics were given for a median of 19 days
(range: 0e54). Flucloxacillin without vancomycin was used in
51%, vancomycin without flucloxacillin in 19%, with both flu-
cloxacillin and vancomycin used in 27%. Aminoglycosides were
used in 41%. Antibiotics were given for a median duration of 21
days in complicated disease compared with 19 days in un-
complicated cases.
In nine patients the antibiotic course was curtailed by death
or discharge to another unit; two had incomplete data on
curtailment. Of 16 patients receiving antibiotics for less than
two weeks, seven had their course curtailed, leaving 79 in
whom the association between antibiotic duration and out-
comes could be determined. Examining antibiotic duration by
Table I
Characteristics of the whole cohort of 90 infants with Staphylo-
coccus aureus bacteraemia
Characteristics Values
Demographics
Gestational age at birth (weeks)a 27 (23e41)
Birth weight (g)a 846 (434e3840)
Male gender 49 (54%)
Inborn 66 (73%)
Characteristics at time of positive culture
Postnatal age (days)a 16 (0e116)
Corrected GA at episode (weeks)a 31 (23e53)
Clinical sepsis 88 (98%)
Classical clinical S. aureus disease 10 (11%)
TPN within 48 h of culture 54 (60%)
Enteral feeds during culture
Full 30 (33%)
Partial 49 (54%)
None 10 (10%)
Central line when S. aureus isolated 52 (58%)
MSSA 84 (93%)
MRSA 6 (7%)
Treatment
Total duration appropriate antibiotics (days)a 19 (0e54)
Duration of antibiotics
0e13 days 16 (18%)
14e27 days 52 (58%)
28 days 21 (23%)
Vancomycin used 41 (46%)
Central line removed during infection 40 (44%)
Complicated S. aureus infection (plastic
device remaining in situ or difficult-
to-penetrate site)
17 (19%)
Antibiotics curtailed by death or discharge 9 (10%)
Outcomes
Any adverse outcome 40 (44%)
Death 7 (8%)
Recurrent S. aureus infection 4 (4%)
Recurrent S. aureus bacteraemia
Breakthrough during primary
antibiotic course
1
After completing antibiotics 0
GA, gestational age; TPN, total parenteral nutrition; MSSA, meticillin-
susceptible S. aureus; MRSA, meticillin-resistant S. aureus.
a Median (range).
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group (<14 days, 14e27 days, >27 days) there were no sta-
tistically significant differences in any parameter, but all those
treated for <14 days had uncomplicated disease (Table II).
On univariate analysis, patients with adverse outcomes
were more likely to be of low gestation or birth weight and to
have complicated disease, and had a higher CRP (Table III). In
stepwise logistic regression analysis, retained variables showed
that the odds for adverse outcome increased with maximum
CRP (odds ratio: 1.009; 95% confidence interval: 1.000e1.018),
were inversely related to birth weight (0.998; 0.996e0.999),
and increased in the presence of complicated disease (16.97;
2.55e113.0).
Deaths in S. aureus bacteraemia
In three of the seven infants who died, staphylococcal sepsis
was a stated cause of death. However, three others died soon
after their positive S. aureus blood culture, suggesting that
S. aureus infection contributed to death. Most who died were
<26 weeks of gestation or <1000 g birth weight. The only term
infant who died had harlequin ichthyosis, with impaired cuta-
neous barrier function and a central line left in place. Both
infants with MRSA who died received vancomycin. Median time
from positive S. aureus blood culture to death was two days
(range: 1e19).
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Figure 1. Gestation, birth weight, postnatal age distribution, and duration of antibiotic therapy. There was a preponderance of low
gestation and low birth weight infants with peak incidence in the second week of life.
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Discussion
This study has described the clinical features of Staphylo-
coccus aureus bacteraemia in a large cohort of infants
admitted to neonatal units. The patients were predominantly
preterm and many had associated conditions. There were high
rates of complications and mortality, attributable to both
S. aureus disease and underlying conditions. A predominance
of disease at lower birth weight has been previously reported.2
Although 11% had a focus typical of S. aureus disease, the
majority had bacteraemia without any focus.
Patients with adverse outcomes had lower gestation and
birth weight, higher CRP and were more likely to have
complicated disease, including retained central venous lines.
This is consistent with research suggesting that central cath-
eter retention is associated with adverse outcomes in neonates
Table II
Characteristics and outcomes for the 79 patients whose antibiotic course was not curtailed by death or discharge
Characteristics and outcomes Duration of appropriate antibiotics P-value
0e13 days 14e27 days 28 days
(N ¼ 9) (N ¼ 51) (N ¼ 19)
Patient demographics
Gestation (weeks)a 28 (23e41) 28 (23e41) 27 (24e38) 0.364
Birth weight (g)a 990 (500e3840) 890 (590e3075) 800 (530e2990) 0.894
Infection episode
Corrected GA at episode (weeks)a 34 (29e44) 31 (23e41) 32 (24e53) 0.156
Clinical sepsis 8 51 19 0.11
Maximum CRP within 72 ha 24 (0e148) 47 (0e280) 57 (0e340) 0.310
Organism, no. (%)
MSSA 9 50 16 0.103
MRSA 0 1 3
Central line when S. aureus isolated 4 29 11 0.84
Central line not removed 0 4 3 0.38
Complicated (plastic device remaining in situ
or difficult-to-treat site)
0 9 5 0.24
Outcomes
Any adverse outcome 2 21 9 0.46
Recurrent S. aureus infection 0 3 1 1.00
Death 0 0 0 e
GA, gestational age; CRP, C-reactive protein; MSSA, meticillin-susceptible S. aureus; MRSA, meticillin-resistant S. aureus.
a Median (range).
Table III
Characteristics of patients with and without adverse outcomes
Characteristics No adverse outcome (N ¼ 50) Adverse outcome present (N ¼ 40) P-value
Demographics
Gestation (weeks)a 28.5 (23e41) 25.5 (23e37) 0.001
Birth weight (g)a 980 (500e3840) 760 (434e2990) 0.006
Male sex 26 (52%) 23 (58%) 0.60
Episode
Postnatal age (days)a 13 (1e110) 22.5 (0e116) 0.23
Corrected GA at episode (weeks)a 32.0 (26e53) 30.5 (23e44) 0.051
Maximum CRP within 72 ha 32 (0e193) 63 (0e340) 0.023
Central line when S. aureus isolated 31 (62%) 21 (53%) 0.44
Organism: MRSA 1 (2%) 5 (13%) 0.09
Treatment
Total duration appropriate antibiotics (days)a 20 (0e50) 17 (0e54) 0.81
Vancomycin used 19 (38%) 22 (55%) 0.084
Central line removed during infection 28 (56%) 12 (30%) 0.026
Complicated (plastic device remaining in situ
or difficult-to-treat site)
3 (6%) 14 (35%) 0.001
GA, gestational age; CRP, C-reactive protein; MRSA, meticillin-resistant S. aureus.
Analysis performed on all 90 patients.
a Median (range).
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with S. aureus or Gram-negative bacteraemia.15 In logistic
regression, low birth weight, high CRP, and complicated dis-
ease carried an increased risk for adverse outcomes. These
findings are limited by our study’s retrospective design.
Although patients with persisting disease markers were inves-
tigated for metastatic foci, this was decided individually by
discussion between clinicians and microbiologists, with no
fixed protocols for repeat blood cultures, further investigation,
or antibiotic duration.
The guidelines for adults and children define uncomplicated
disease by exclusion of endocarditis, with no metastatic sites
or implanted prosthesis, and rapid disease control.11 This
definition cannot be directly applied in neonates, in whom it is
hard to exclude bacterial endocarditis. To retain the concept
of difficult source control, complicated disease was defined as
the presence of a central line or other foreign material which
was not removed, a focus which was hard for antibiotics to
penetrate, or metastatic sites of infection. Using this defini-
tion, complicated disease was not a risk factor for adverse
outcome or recurrence, but all complicated cases had planned
antibiotic courses of over two weeks. The favourable outcomes
with less than two weeks of therapy may have been achieved
because none had complicated disease.
There was no association between antibiotic duration and
complications or recurrence. Only one infant was identified
with bacterial endocarditis. In adults, Asgeirsson et al. found
that in complicated S. aureus bacteraemia, duration of intra-
venous antibiotic therapy was 16 days in those experiencing a
relapse and 30 days in those who did not.6 However, Walker
et al. did not find an association between curtailed antibiotic
therapy and recurrence.5 They found that recurrence was
associated with keeping a central line in place and with
glycopeptide treatment of meticillin-susceptible S. aureus.
No cases of recurrent bacteraemia were found after finish-
ing antibiotics, and only one case of breakthrough bacteraemia
occurred during treatment. Preterm infants in this study stayed
in hospital for many weeks before discharge home, allowing
detection of early recurrence. Although some patients were
transferred in from other areas, 73% were inborn and would
have been readmitted to the same hospital with recurrent
disease. Although late recurrence rates could have been
slightly underestimated, they were certainly very low. As
endocarditis is a major factor in adult recurrent disease, this
suggests that the newborn may be relatively well protected
against S. aureus endocarditis. In vitro, shear stress reduces
adherence of S. aureus to endothelial cells.16 Children and
newborn infants have a higher cardiac output per unit body
weight than adults, with the highest values in extremely pre-
term infants.17e19 This could produce greater shear forces at
the endothelial interface and protect the normally vulnerable
neonate against S. aureus endocarditis.
The proportion of our patients with MRSA was only 7%, com-
parable with 8% found in another UK series, but lower than the
33% reported in a US series.1,2 A non-significant trend for more
adverse outcomes with MRSA was found. Enhanced surveillance
ofMRSAbacteraemia in children reporteda lowproportion (1.9%)
with endocarditis.20 However, in a series of MRSA bacteraemia
cases, Chuang et al. reported recurrent bacteraemia in seven out
of 82 (8.5%) infants; all were treated with 14 days of vanco-
mycin and four had catheter-related infection.21
Most infants who died were extremely preterm, suggesting
that S. aureus bacteraemia may be particularly hazardous in
this group. The approach to source control was adequate in
those who died; only one infant with severe vascular access
difficulties had a central line left in place. The median time
from positive S. aureus blood culture to death was two days.
Our study is the largest series of neonatal S. aureus bac-
teraemia relating clinical outcomes to duration of antibiotic
treatment. No link was found between duration of antibiotic
therapy and adverse outcomes, but clinicians used longer
courses of antibiotics for more complicated cases. Rates of
endocarditis and recurrent bacteraemia were low. Given the
problem of early mortality, the clinical priority is to implement
strategies to prevent colonization and reduce early mortality.
Removal of protected sources such as central lines may also be
important to prevent recurrence. We suggest that in neonates
with S. aureus bacteraemia it is reasonable to apply the adult
recommendations for antibiotic therapy of 14 days in uncom-
plicated cases, and longer for cases with inadequate source
control.
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